Most people have never heard of Elementis (LSE:ELM), yet plenty of them use its chemistry every day. When emulsion paint stays on the roller and off the carpet, or a foundation glides on smoothly without separating in the bottle, a rheology modifier is often doing the job. These additives control how a liquid flows, thickens and settles, and they are Elementis's speciality.

The FTSE 250 group makes its money by selling small quantities of high-value ingredients to large formulators. An additive may be a tiny share of a paint or cosmetic's recipe, but it strongly influences how the product performs, so customers tend to be slow to switch once a formula is approved. At the heart of the Business is hectorite, a natural white clay. Elementis describes its Californian hectorite mine as the largest known high-grade commercial deposit, with more than 50 years of reserves, and that asset underpins much of its pitch to investors.

After two years of pruning, Elementis is now a simpler company built around two divisions, Coatings and Personal Care. Can this leaner shape turn Margin gains into lasting growth?

How the business makes money

Coatings is the larger division. It supplies thickeners, dispersants and other additives for architectural (decorative) paints, industrial and automotive coatings and niche uses such as tile adhesives and battery materials. A smaller Energy business, run from the St. Louis plant, also sits alongside it. Personal Care supplies rheology modifiers based on hectorite and organoclays for colour cosmetics, skincare and suncare, together with active ingredients for antiperspirants.

Personal Care is the jewel. In the six months to 30 June 2026 it generated Revenue of $109.2m at an adjusted Operating Margin of 38.1%, while Coatings brought in $209.0m at 20.7%.

Recent performance

The interim results, published on 30 July 2026, were the strongest for some time. Revenue for the six months to 30 June 2026 increased by 9.4% to $318.2m, or 4.7% on an organic constant-currency basis, with currency and the Alchemy Acquisition making up the rest. Adjusted operating profit climbed 16.4% to $73.2m, lifting the adjusted margin from 21.6% to 23.0%. Adjusted Diluted Earnings per Share jumped 28.8% to 8.5 cents, helped by a smaller share count after buybacks, and the Interim Dividend was raised 15.4% to 1.5 cents.

Coatings was the standout. Organic Sales rose 5.6%, and segment profit increased by almost a quarter, thanks to higher prices and volumes, cost savings and strength in Asia and Europe offsetting weakness in North America. Personal Care grew only 2.9% organically as the Americas lagged, although Asia delivered mid-teens growth and launches in skincare and suncare drove double-digit sales increases in those categories.

Cash flow was less impressive. Free Cash Flow in the half was $13.3m, compared with $15.4m a year earlier, partly because the company bought raw materials early in response to the Middle East conflict. Net Debt nonetheless fell to $163.8m at 30 June 2026 from $185.4m at the end of 2025, or 1.1 times EBITDA.

This built on 2025, when, as originally reported, revenue slipped 1.0% to $597.5m but adjusted operating profit rose to $126.7m, a 21.2% margin, and the dividend increased to 4.3 cents.

Strategy and catalysts

Chief executive Luc van Ravenstein, who took over in April 2025, launched a plan called "Elevate Elementis". Its medium-term targets are mid-single-digit revenue growth through the cycle, an adjusted operating margin of at least 23%, operating cash conversion above 90% over three years and a return on Capital employed, excluding goodwill, above 30%. On margin, the first half has already reached the target.

The portfolio has been sharply narrowed. The talc business was sold in 2025, and the pharmaceutical Manufacturing unit was sold to Associated British Foods on 1 June 2026 for an Enterprise value of €34.3m. Around $35m of net proceeds are being returned through a £25m share buyback, following a £40m programme completed in 2025. In November 2025 Elementis bought Alchemy Ingredients, a natural skincare ingredients specialist, for $22m.

Innovation is the main growth lever. Management expects double-digit annual growth in hectorite sales in both divisions, and first-half launches included battery slurry additives. A further $10m cost programme has $4m of savings targeted for 2026.

Valuation talking points

In late July 2026, shortly before the interim results, the shares traded at around 169p, giving a Market Value of roughly £960m. They had traded between 136p and 179.6p over the previous 52 weeks, according to StockAnalysis, which also showed a trailing price-to-earnings ratio of about 22 and a Dividend Yield of about 1.9%. Brokers tracked by the same service had an average price target of 202p.

Company-compiled consensus, published on 29 July 2026, put adjusted operating profit for 2026 at $132.5m, and management said it was confident of meeting expectations. The key issue is whether the market prices Elementis as a cyclical paint supplier or a premium ingredients business.

The bull case

  • The Californian hectorite reserve is a scarce, long-lived asset that competitors cannot easily copy.
  • Margins have already reached the 23% target, with Coatings' margin up 250 basis points year on year.
  • A cleaner portfolio, falling debt and continued Buybacks are driving faster earnings-per-share growth.
  • Launches in skincare, suncare and battery materials offer growth beyond traditional paint markets.

The bear case

  • Coatings Demand is still subdued in North America and remains tied to construction and industrial cycles.
  • Personal Care's organic growth of 2.9% in the half was modest for the group's highest-margin division.
  • Free cash flow fell in the first half, and cash conversion targets have yet to be proven.
  • The Middle East conflict could raise input costs or disrupt supply, and dollar reporting adds currency risk for sterling investors.
  • Asset sales have made the group smaller, so more depends on organic execution.

The bottom line

Elementis sells ingredients that consumers never notice but formulators depend on, backed by a mineral deposit that is difficult to replicate. Under Luc van Ravenstein, it has sold weaker assets, raised margins to its target and returned surplus cash, and the first half of 2026 showed the benefits.

The next test is growth. Investors will want to see Personal Care recover in the Americas, Coatings withstand a patchy industrial economy and cash conversion improve. If those pieces fall into place, the argument for the stock becomes about quality rather than recovery. If they do not, a strong margin story may struggle to lift the valuation much further.